收费全文 | 104篇 |
免费 | 11篇 |
儿科学 | 1篇 |
基础医学 | 2篇 |
临床医学 | 8篇 |
内科学 | 14篇 |
神经病学 | 3篇 |
外科学 | 45篇 |
综合类 | 1篇 |
预防医学 | 2篇 |
眼科学 | 1篇 |
药学 | 37篇 |
中国医学 | 1篇 |
2021年 | 2篇 |
2020年 | 3篇 |
2019年 | 5篇 |
2018年 | 4篇 |
2017年 | 3篇 |
2016年 | 4篇 |
2015年 | 7篇 |
2014年 | 5篇 |
2013年 | 22篇 |
2012年 | 5篇 |
2011年 | 12篇 |
2010年 | 10篇 |
2009年 | 2篇 |
2008年 | 6篇 |
2007年 | 3篇 |
2006年 | 4篇 |
2005年 | 2篇 |
2003年 | 1篇 |
2001年 | 1篇 |
1999年 | 3篇 |
1996年 | 2篇 |
1995年 | 1篇 |
1993年 | 1篇 |
1992年 | 1篇 |
1989年 | 1篇 |
1988年 | 1篇 |
1985年 | 1篇 |
1982年 | 1篇 |
1980年 | 1篇 |
1979年 | 1篇 |
Methods: This was a prospective observational analysis of patients diagnosed with antimuscarinic delirium and treated in consultation with a regional PC. Certified Specialists in Poison Information (CSPIs) use a clinical guideline to recommend the use of physostigmine. Using a previously derived altered mental status score, we quantified the rate of delirium improvement with physostigmine compared to non-antidote therapy two hours after initial patient identification. We also recorded adverse events (defined a priori as bradycardia, vomiting, seizures) and resource utilization (intubation and physical restraint).
Results: We identified 245 patients and included 154 in the analysis. The most common exposure classes were antihistamines (68%), analgesics (19%), and antipsychotics (19%). CSPIs recommended physostigmine in 81% (125) of cases and the treatment team administered it in 37% (57) of these. We observed delirium control in 79% of patients who received physostigmine versus 36% of those who did not. The odds of delirium control were six times greater for patients receiving physostigmine than for patients treated with non-antidote therapy (OR 6.6). Adverse events were rare and did not differ significantly between the groups. Physostigmine was not associated with changes in the incidence of intubation or restraint.
Conclusions: This study provides further evidence of both the safety and efficacy of physostigmine in the treatment of antimuscarinic delirium. 相似文献
OBJECTIVE
? To show the superior efficacy of fesoterodine over tolterodine extended release (ER) in a placebo‐controlled overactive bladder (OAB) trial with predefined treatment comparisons for both diary measures and patient‐reported outcomes.MATERIALS AND METHODS
? In this 12‐week, double‐blind, double‐dummy trial, subjects reporting >1 urgency urinary incontinence (UUI) episode and ≥8 micturitions per 24 h at baseline were randomized to fesoterodine (4 mg for 1 week, 8 mg for 11 weeks), tolterodine ER 4 mg, or placebo. ? Subjects completed 3‐day bladder diaries, the Patient Perception of Bladder Condition (PPBC) and the Urgency Perception Scale (UPS) at baseline and weeks 1, 4 and 12 and the OAB Questionnaire at baseline and week 12.RESULTS
? A total of 2417 subjects were randomized. At week 12, fesoterodine 8 mg showed superiority over tolterodine ER 4 mg and placebo on UUI episodes (primary endpoint), micturitions, urgency and most other diary endpoints, and on the PPBC, UPS and all OAB Questionnaire scales and domains (all P < 0.05). ? Superiority of fesoterodine 8 mg over tolterodine ER 4 mg was seen as early as week 4 (3 weeks after escalation to fesoterodine 8 mg). At week 1, fesoterodine 4 mg was superior to placebo on most diary variables, the PPBC and the UPS (all P < 0.05). Dry mouth and constipation rates were 28% and 4% with fesoterodine, 13% and 3% with tolterodine ER, and 5% and 2% with placebo. ? Discontinuation rates as a result of adverse events were 5%, 3% and 2% for fesoterodine, tolterodine ER and placebo, respectively.CONCLUSIONS
? In this randomized study, which is the largest to compare antimuscarinic efficacy performed to date, fesoterodine 8 mg was superior to tolterodine ER 4 mg for UUI episodes, micturitions and urgency episodes, as well as for self‐reported patient assessments of bladder‐related problems, urgency, symptom bother and health‐related quality of life. ? The superiority of fesoterodine 8 mg over tolterodine ER 4 mg was observed as early as 3 weeks after escalation from fesoterodine 4 mg for most outcomes. These data may have important implications for the clinical management of OAB patients previously treated with tolterodine ER. 相似文献OBJECTIVES
- ? To evaluate the effects of long‐term fesoterodine treatment on health‐related quality of life (HRQL) and treatment satisfaction in subjects with overactive bladder (OAB) symptoms.
- ? To determine the impact of gender and age on these effects.
PATIENTS AND METHODS
- ? This is a post hoc analysis of data pooled from identically designed open‐label extensions of two randomized, double‐blind, 12‐week fesoterodine studies.
- ? Initial treatment was once‐daily fesoterodine 8 mg; subjects had the opportunity to receive open‐label fesoterodine for ≥24 months.
- ? After 1 month, subjects could elect dose reduction to 4 mg and subsequent re‐escalation to 8 mg; dose reduction and re‐escalation were each allowed once annually.
- ? Changes in scores on the King's Health Questionnaire (KHQ), International Consultation on Incontinence Questionnaire–Short Form (ICIQ‐SF) and a Likert scale evaluating severity of bladder‐related problems were assessed at open‐label baseline and months 12 and 24; treatment satisfaction was assessed at open‐label baseline and at months 4, 12 and 24.
RESULTS
- ? A total of 864 enrolled subjects were included (men, n= 182; women, n= 682; aged <45 years, n= 134; 45–64 years, n= 432; 65–74 years, n= 204; ≥75 years, n= 94); most subjects (77%) who continued treatment maintained the 8‐mg dose.
- ? Among subjects in the overall population, there were significant improvements in all KHQ domains, ICIQ‐SF scores, and bladder‐related problems at open‐label baseline vs double‐blind baseline (P < 0.05); additional significant improvements were observed at months 12 and 24 vs open‐label baseline in all outcomes (P < 0.05) except for the KHQ General Health Perception domain.
- ? When data were stratified by gender or age, significant improvements at open‐label baseline vs double‐blind baseline were further significantly enhanced or sustained at months 12 and 24 for most KHQ domains, and for ICIQ‐SF scores and bladder‐related problems for all groups. Women had significantly greater improvements than men in the KHQ Emotion (P= 0.0173) and Severity/Coping (P= 0.0112) domains and ICIQ‐SF scores (P= 0.0276) during open‐label treatment. Subjects aged <45 years had significantly greater improvement in the Personal Relationships domain compared with those aged 45–64 years (P= 0.0357) and in the Sleep/Energy domain compared with all other groups (all P < 0.02).
- ? Treatment satisfaction was high (≥92%) throughout open‐label treatment regardless of gender or age.
CONCLUSIONS
- ? Long‐term fesoterodine treatment was associated with sustained improvement in measures of health‐related quality of life and bladder‐related problems and with high treatment satisfaction in subjects with overactive bladder symptoms.
- ? Effects of gender and age were minimal.
![点击此处可从《International journal of urology》网站下载免费的PDF全文](/ch/ext_images/free.gif)